Evidence map›Paper›PMID 28842811›Full record

ArticleMolecular imaging and biology2018

Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody.

Julia Baguña Torres, James C Knight, Michael J Mosley, Veerle Kersemans, Sofia Koustoulidou, Danny Allen, Paul Kinchesh, Sean Smart, Bart Cornelissen

Open access · hybridAbstract read
In one paragraph

Article in Molecular imaging and biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Molecular Imaging of p53 in Mouse Models of Cancer Using a Radiolabeled Antibody TAT Conjugate with SPECT.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Article
  5. Review
  6. Review
  7. Claudin and pancreatic cancer.Frontiers in oncology · 2023
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Targeting claudins in cancer: diagnosis, prognosis and therapy.American journal of cancer research · 2021
    Review
  13. Review
  14. Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020
    Article
  15. Claudin-1, A Double-Edged Sword in Cancer.International journal of molecular sciences · 2020
    Review
  16. Review
  17. Tumor Imaging Using Radiolabeled Matrix Metalloproteinase-Activated Anthrax Proteins.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
  18. Review
  19. Article
  20. Convenient Preparation ofPharmaceuticals (Basel, Switzerland) · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Julia Baguña TorresCR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK.
James C KnightCR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK.
Michael J MosleyCR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK.
Veerle KersemansCR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK.
Sofia KoustoulidouCR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK.
Danny AllenCR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK.
Paul KincheshCR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK.
Sean SmartCR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK.
Bart CornelissenCR-UK/MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Old Road Campus Research Building, Off Roosevelt Drive, Oxford, OX3 7DQ, UK. bart.cornelissen@oncology.ox.ac.uk.
University of Oxford · GBCRUK/MRC Oxford Institute for Radiation Oncology · GB

Funding

Cancer Research UK 16466Cancer Research UK 23970Medical Research Council
6 · The paper itself

Abstract

purposeDespite its widespread use, the positron emission tomography (PET) radiotracer 2-deoxy-2-[ PROCEDURES: The ability of [

resultsHigh uptake of [

conclusions[

Indexed as

Imaging, Three-DimensionalAdenocarcinomaAnimalsAntibodies, MonoclonalAutoradiographyCarcinoma, Pancreatic DuctalClaudin-4HumansIndium RadioisotopesMice, Inbred BALB CMice, NudePentetic AcidRadiopharmaceuticalsReproducibility of ResultsTissue DistributionXenograft Model Antitumor AssaysAntibodies, MonoclonalClaudin-4Indium-111Indium RadioisotopesPentetic AcidRadiopharmaceuticalsClaudin-4Molecular imagingPancreatic ductal adenocarcinomaSPECT

Identifiers

PMID28842811
PMCPMC5862916
OpenAlexW2746769760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.